\nIpamorelin is a cutting-edge pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Renowned for its ability to stimulate the pituitary gland, Ipamorelin promotes the natural release of growth hormone (GH). This peptide is highly regarded for its potential to support lean muscle growth, aid in weight management, and enhance overall wellness. Unlike other growth hormone-releasing peptides, Ipamorelin has minimal impact on key hormones such as:<\/p>\n
- \n
- Thyroid-stimulating hormone (TSH)<\/li>\n
- Luteinizing hormone (LH)<\/li>\n
- Prolactin<\/li>\n
- Follicle-stimulating hormone (FSH)<\/li>\n
- Adrenocorticotropic hormone (ACTH)<\/li>\n
- Cortisol<\/li>\n<\/ul>\n
As a member of the Growth Hormone-Releasing Peptides (GHRPs) family, Ipamorelin is celebrated for its ability to elevate GH levels, offering a range of potential clinical benefits, including:<\/p>\n
- \n
- Improved body composition through fat reduction and weight management<\/li>\n
- Enhanced skin elasticity and function<\/li>\n
- Reduced cortisol levels for better stress management<\/li>\n
- Increased energy levels and improved sleep quality<\/li>\n<\/ul>\n
Ipamorelin is often compared to GHRP-6 and GHRP-2 due to its similar mechanisms of action and functionality, making it a popular choice for research and clinical studies.<\/p>\n
\nPotential Benefits of Ipamorelin Under Investigation<\/strong><\/p>\n
1. Counteracting Glucocorticoid Side Effects<\/strong>
\nLong-term glucocorticoid use can lead to adverse effects such as inflammation, reduced lean muscle mass, and increased body fat. Research suggests that Ipamorelin may help mitigate these effects by stimulating the pituitary gland, potentially reversing muscle wasting and improving nitrogen balance in muscles.<\/p>\n2. Protection Against Bone Loss<\/strong>
\nProlonged glucocorticoid use is associated with decreased bone density and increased fracture risk. Studies indicate that Ipamorelin may help counteract bone loss by promoting bone formation and enhancing bone mineral density, as demonstrated in preclinical trials.<\/p>\n3. Potential Support for Diabetes Management<\/strong>
\nEmerging research on diabetic models suggests that Ipamorelin may stimulate insulin release by interacting with calcium channels in pancreatic cells. This finding highlights its potential role in supporting metabolic health and diabetes prevention.<\/p>\n4. Diagnostic Applications in Cancer and Heart Failure<\/strong>
\nIpamorelin\u2019s interaction with the ghrelin receptor has sparked interest in its use as a positron emission tomography (PET) probe. Preliminary studies suggest it could enhance diagnostic accuracy for certain cancers and heart failure, offering a promising tool for medical imaging.<\/p>\n5. Post-Operative Ileus (POI) Recovery<\/strong>
\nPost-operative ileus, a temporary gastrointestinal paralysis following surgery, can delay recovery. Ipamorelin has shown potential in reducing recovery time and improving nutrient absorption in individuals affected by POI, making it a valuable area of study for post-surgical care.<\/p>\n
\nIpamorelin 5mg Product Details<\/strong><\/p>\n
- \n
- CAS Number:<\/strong> 170851-70-4<\/li>\n
- Molecular Formula:<\/strong> C38H49N9O5<\/li>\n
- Sequence:<\/strong> Aib-His-D-2-Nal-D-Phe-Lys-NH2<\/li>\n
- Molar Mass:<\/strong> 711.85 g\/mol<\/li>\n
- Half-Life:<\/strong> Approximately 2 hours<\/li>\n
- Purity:<\/strong> Minimum 99%<\/li>\n
- Form:<\/strong> Lyophilized powder in a sterile glass vial<\/li>\n
- Storage:<\/strong> Refrigerate after reconstitution<\/li>\n
- Dosage:<\/strong> 5mg per vial<\/li>\n<\/ul>\n
Important Note:<\/strong>
\nThis product is intended solely for in vitro research purposes by licensed professionals. It is not approved by the FDA for human or animal consumption and should not be misbranded, misused, or mislabeled as a drug, supplement, food, or cosmetic.<\/p>\n
\nReferences<\/strong><\/p>\n
- \n
- Ipamorelin, the first selective growth hormone secretagogue. PubMed<\/a><\/li>\n
- Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid-treated rats. PubMed<\/a><\/li>\n
- The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. PubMed<\/a><\/li>\n
- The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. PubMed<\/a><\/li>\n
- Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. PubMed<\/a><\/li>\n
- Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor. PubMed<\/a><\/li>\n
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. PubMed<\/a><\/li>\n
- Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. PubMed<\/a><\/li>\n
- Ipamorelin Peptide: Exploring its Potential in Growth Hormone Stimulation and Health. Peptide Information<\/a><\/li>\n<\/ol>\n
\nWhy Choose Elitebiogenix for Ipamorelin 5mg?<\/strong>
\nAt Elitebiogenix, we provide premium-quality peptides for research purposes. Our Ipamorelin 5mg is rigorously tested to ensure purity and potency, making it an ideal choice for laboratory studies. Explore the potential of Ipamorelin with confidence, backed by our commitment to excellence in research-grade products.<\/p>\n[\/vc_column_text][\/vc_column][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_direction_desktop=”default” column_element_spacing=”default” desktop_text_alignment=”default” tablet_text_alignment=”default” phone_text_alignment=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_backdrop_filter=”none” column_shadow=”none” column_border_radius=”none” column_link_target=”_self” column_position=”default” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1\/12″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][\/vc_column][\/vc_row]\n","protected":false},"excerpt":{"rendered":"\n- \n
![](\"https:\/\/elite.rataserver.ca\/wp-content\/uploads\/2024\/04\/verified.png\")
CAS Number: <\/strong>170851-70-4<\/li>\nFormula:<\/strong>C38<\/sub>H49<\/sub>N9<\/sub>O5<\/sub><\/li>\nSequence: <\/strong>Aib-His-D-2-Nal-D-Phe-Lys-NH2<\/li>\nMolar Mass: <\/strong>711.85 g\/mol<\/li>\nClass: <\/strong>Peptide<\/li>\nStorage: <\/strong>Keep refrigerated upon reconstitution.<\/li>\n<\/ul>\n<\/div>\n
- Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid-treated rats. PubMed<\/a><\/li>\n
- Molecular Formula:<\/strong> C38H49N9O5<\/li>\n
- CAS Number:<\/strong> 170851-70-4<\/li>\n
![](\"https:\/\/elite.rataserver.ca\/wp-content\/uploads\/2024\/04\/free-shpping.png\")
<\/div>\n